Evidence map›Paper›PMID 21931646›Full record

ArticlePloS one2011

GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.

Valeria Judkowski, Alcinette Bunying, Feng Ge, Jon R Appel, Kingyee Law, Atima Sharma, Claudia Raja-Gabaglia, Patricia Norori, Radleigh G Santos, Marc A Giulianotti and 4 more

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Valeria JudkowskiTorrey Pines Institute for Molecular Studies, San Diego, California, United States of America.
Alcinette Bunying
Feng Ge
Jon R Appel
Kingyee Law
Atima Sharma
Claudia Raja-Gabaglia
Patricia Norori
Radleigh G Santos
Marc A Giulianotti
Mark K Slifka
Daniel C Douek
Barney S Graham
Clemencia Pinilla

Funding

YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI FRUH, KLAUS J · 1985 to 2011
$140.8M
Development of a Safe and Effective Vaccine Against West Nile VirusU01AI082196 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SLIFKA, MARK K · 2009 to 2012
$7.1M
Development of a Yellow Fever Vaccine for Vulnerable PopulationR44AI079898 · NIAID · NAJIT TECHNOLOGIES, INC. · PI AMANNA, IAN JAMES, SLIFKA, MARK K · 2011 to 2020
$6.2M
REPRODUCTIVE STEROIDS AND EXPERIMENTAL STROKEK01RR000163 · NCRR · OREGON HEALTH AND SCIENCE UNIVERSITY · PI MURPHY, STEPHANIE J · 2000 to 2004
$479k
NCRR NIH HHS K01 RR000163NCRR NIH HHS P51 RR000163NCRR NIH HHS RR00163NIAID NIH HHS HHSN266200400080C/N01-AI-40080NIAID NIH HHS N01 AI040080NIAID NIH HHS R44 AI079898NIAID NIH HHS U01 AI082196
6 · The paper itself

Abstract

The threat of bioterrorism with smallpox and the broad use of vaccinia vectors for other vaccines have led to the resurgence in the study of vaccinia immunological memory. The importance of the role of CD4+ T cells in the control of vaccinia infection is well known. However, more CD8+ than CD4+ T cell epitopes recognized by human subjects immunized with vaccinia virus have been reported. This could be, in part, due to the fact that most of the studies that have identified human CD4+ specific protein-derived fragments or peptides have used IFN-γ production to evaluate vaccinia specific T cell responses. Based on these findings, we reasoned that analyzing a large panel of cytokines would permit us to generate a more complete analysis of the CD4 T cell responses. The results presented provide clear evidence that TNF-α is an excellent readout of vaccinia specificity and that other cytokines such as GM-CSF can be used to evaluate the reactivity of CD4+ T cells in response to vaccinia antigens. Furthermore, using these cytokines as readout of vaccinia specificity, we present the identification of novel peptides from immunoprevalent vaccinia proteins recognized by CD4+ T cells derived from smallpox vaccinated human subjects. In conclusion, we describe a "T cell-driven" methodology that can be implemented to determine the specificity of the T cell response upon vaccination or infection. Together, the single pathogen in vitro stimulation, the selection of CD4+ T cells specific to the pathogen by limiting dilution, the evaluation of pathogen specificity by detecting multiple cytokines, and the screening of the clones with synthetic combinatorial libraries, constitutes a novel and valuable approach for the elucidation of human CD4+ T cell specificity in response to large pathogens.

Indexed as

Amino Acid SequenceAntigen-Presenting CellsAntigensAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineCells, CulturedGranulocyte-Macrophage Colony-Stimulating FactorHLA-DR AntigensHumansInterferon-gammaSmallpoxSmallpox VaccineTumor Necrosis Factor-alphaVaccinationAntigensAntigens, ViralGranulocyte-Macrophage Colony-Stimulating FactorHLA-DR AntigensInterferon-gammaSmallpox VaccineTumor Necrosis Factor-alpha

Identifiers

PMID21931646
PMCPMC3170313

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.